Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7388941 | Value in Health | 2018 | 6 Pages |
Abstract
Medicaid reimbursement for DAAs differs across states after controlling for HCV infection prevalence. A third of states contributed more than 5% to 15% of pharmacy reimbursements to DAAs. Medications for HCV infection are only one class of highly priced specialty drugs. Innovative policy strategies are needed for health systems to manage coverage for an increasing number of expensive specialty medications indicated for an increasing number of patients.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Christine Y. PhD, MSc, Fang PhD, Nicole MPH, Caitlin MSc, Paul PharmD, Anita K. PharmD, MPH, DrPH,